Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Belzutifan in Advanced Renal Cell Carcinoma
2022-502123-21-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised trial of belzutifan in renal cell carcinoma (RCC) (2 arms), sponsored by Merck & Co. Primary endpoint: Objective Response Rate (ORR) per RECIST 1.1 by BICR. Started Dec 2020; status: completed.
02
Drugs
belzutifan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2022-502123-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502123-21-00.